Renaissance Technologies LLC lowered its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 44.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,500 shares of the medical instruments supplier's stock after selling 5,900 shares during the period. Renaissance Technologies LLC owned 0.14% of Mesa Laboratories worth $989,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Franklin Resources Inc. lifted its position in Mesa Laboratories by 27.8% during the third quarter. Franklin Resources Inc. now owns 6,444 shares of the medical instruments supplier's stock valued at $828,000 after acquiring an additional 1,403 shares during the last quarter. Barclays PLC increased its position in shares of Mesa Laboratories by 357.4% during the third quarter. Barclays PLC now owns 8,837 shares of the medical instruments supplier's stock worth $1,148,000 after purchasing an additional 6,905 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Mesa Laboratories by 21.8% in the 3rd quarter. Principal Financial Group Inc. now owns 35,107 shares of the medical instruments supplier's stock worth $4,559,000 after purchasing an additional 6,292 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Mesa Laboratories by 29.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,406 shares of the medical instruments supplier's stock worth $1,092,000 after buying an additional 1,906 shares during the last quarter. Finally, Pacer Advisors Inc. raised its stake in Mesa Laboratories by 4.3% in the fourth quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier's stock valued at $231,000 after buying an additional 73 shares during the last quarter. Institutional investors own 90.60% of the company's stock.
Mesa Laboratories Stock Performance
NASDAQ:MLAB traded up $3.66 during trading hours on Friday, hitting $119.06. 27,293 shares of the company were exchanged, compared to its average volume of 39,268. The company's 50 day moving average price is $120.91 and its 200-day moving average price is $126.74. The stock has a market capitalization of $646.97 million, a price-to-earnings ratio of -2.57 and a beta of 0.97. Mesa Laboratories, Inc. has a 52-week low of $83.68 and a 52-week high of $155.12. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.71 and a quick ratio of 0.53.
Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, beating analysts' consensus estimates of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. As a group, research analysts forecast that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.
Mesa Laboratories Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 16th. Shareholders of record on Friday, May 30th will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.54%. The ex-dividend date of this dividend is Friday, May 30th. Mesa Laboratories's payout ratio is -1.38%.
Insider Activity
In other news, CEO Gary M. Owens sold 21,000 shares of the firm's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total value of $2,602,110.00. Following the transaction, the chief executive officer now directly owns 43,337 shares of the company's stock, valued at approximately $5,369,887.67. This trade represents a 32.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 4.40% of the company's stock.
About Mesa Laboratories
(
Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Featured Articles
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
